Although HER2-overexpressing breast cancers appear seldom to carry BRCA mutations, ovarian cancers have significantly higher numbers of BRCA mutant/HER2 positive cases and this patient population would therefore represent a potential clinical indication for further exploration for this combination [33]. The gene discussed is ERBB2; the disease is ovarian cancer.